Interstitial lung disease
Conditions
Interventions
experimental group:Treatment with pirfenidone
control group:Nil
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pf-ild diagnosed as non IPF; 2. Patients over 18 years old; 3. The patients with diffuse fibrotic pulmonary disease (reticular shadow with tractive bronchiectasis, with or without honeycomb lung) showed more than 10% degree by HRCT examination = 45%; 5. Patients with DLCO predicted value >= 30% - < 80%; 6. Patients with informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects allergic to pirfenidone capsules; 2. In subjects with abnormal liver function, serum alanine aminotransferase, aspartate aminotransferase or bilirubin increased more than 2 times at baseline; 3. Subjects who had received other research drugs (participating in clinical research) within 8 weeks before visit 1; 4. Subjects who had received nidanib treatment within 8 weeks before visit 1; 5. Subjects who had been treated with pirfenidone before; 6. Women of childbearing age who plan to get pregnant or men of childbearing age who plan to have children; 7. Pregnant or lactating women; 8. Patients with other serious persistent diseases or organ system dysfunction (the researchers believe that it may damage the safety of patients or interfere with the safety evaluation of the test drug); 9. Compliance: subjects with known evidence of non-compliance with the trial drug treatment and / or failure to follow the doctor's advice.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung Function; | — |
Secondary
| Measure | Time frame |
|---|---|
| King's short questionnaire for interstitial lung disease;Time of acute exacerbation of interstitial lung disease; | — |
Countries
China
Contacts
Public ContactYing Zhou
Shanghai Pulmonary Hospital Affiliated to Tongji University
Outcome results
None listed